Preventive Effects of Epigallocatechin-3-O-Gallate against Replicative Senescence Associated with p53 Acetylation in Human Dermal Fibroblasts
Table 2
Cell cycle progression in serially passaged RVSMCs (a), HDFs (b), and HACs (c) before and after EGCG treatment.
(a)
RVSMCs
% Cell population
G0/G1
S
G2M
Controla
52.5 ± 4.3
35.7 ± 5.1
11.8 ± 3.3
non-treated
82.1 ± 8.2*
8.4 ± 2.8*
9.5 ± 5.2
EGCG-treated
61.0 ± 4.0*,#
24.4 ± 4.7*,#
14.6 ± 4.6
(b)
HDFs
% Cell population
G0/G1
S
G2M
Controla
52.2 ± 5.2
31.3 ± 4.2
16.5 ± 3.8
non-treated
78.3 ± 7.1*
8.4 ± 3.1*
13.3 ± 4.6
50 μM EGCG-treated
69.4 ± 6.0*,#
15.4 ± 3.6*,#
15.2 ± 4.9
100 μM EGCG-treated
58.1 ± 5.2#
27.2 ± 6.3#
14.7 ± 5.5
(c)
HACs
% Cell population
G0/G1
S
G2M
Controla
71.4 ± 7.1
14.9 ± 5.8
13.7 ± 4.0
non-treated
90.5 ± 8.8*
5.1 ± 2.0*
4.4 ± 1.5*
EGCG-treated
75.6 ± 6.5#
11.7 ± 3.5#
12.7 ± 3.4#
(aProliferating cells at early passage (PN 3 or 5)). All variables were tested in three independent cultures for each experiment, which was repeated twice independently (). The results are reported as a mean ± SD and analyzed by a Tukey HSD test. *P < 0.05 versus control; #P < 0.05 versus non-treated cells.
